[Update on hepatitis C therapy. New drugs, treatment response monitoring and emergence of resistance]
{{output}}
The development of novel direct antiviral agents (DAAs) against hepatitis C virus (HCV) has represented a breakthrough in the treatment of chronic hepatitis C. Telaprevir and boceprevir are the first two protease inhibitor (PI) DAAs to be approved for combinat... ...
